Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, 30310, USA.
Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, 30310, USA.
Cancer Lett. 2018 Jul 28;427:49-62. doi: 10.1016/j.canlet.2018.04.017. Epub 2018 Apr 18.
The folate receptor (FR) is a valued target that is highly expressed in various cancers, which will expedite the development of ligand-receptor binding based cancer therapeutics. In the present investigation, through tissue microarray analysis, we report higher levels of folate receptor expression in prostate cancer (PCa) tissue derived from patients, which were minimal in normal tissue. For folate-receptor based targeted therapy of PCa, we generated novel planetary ball milled (PBM) nanoparticles (NPs) encapsulated with resveratrol (RES), and in combination with docetaxel (DTX) and conjugated with folic acid (FA) on the surface. The cytotoxic effect of FA-conjugated DTX-nanoparticles was found effectual that reduced the concentration of free drug (DTX) to 28 times. Flow cytometry analysis showed a significant increase in the number of apoptotic cells by 30.92% and 65.9% in the FA-conjugated RES and in combination with DTX nanoparticle formulation respectively. However, only 8.9% apoptotic cells were found with control (empty NP). The expressions of NF-kB p65, COX-2, pro (BAX, BAK) and anti-apoptotic (BCL-2, BCL-XL) genes were significantly reduced after treatment with FA-RES + DTX-NP. In addition, the FA-conjugated DTX formulation exhibited additional cytotoxic effects with the down-regulation of survivin and an increased expression of Cleaved Caspase-3 in PCa cells. Further, we observed that treating DTX resistant PCa cells with FA-RES + DTX-NP exhibited a reversal of the ABC-transporter markers thereby limiting the multidrug resistance phenotype of the cancer cells. Our results strongly suggested that FA conjugated nanoparticle drugs acted as effective inhibitors of drug efflux that effectually enhances the intracellular concentration of the drug to exhibit their cytotoxic effect.
叶酸受体(FR)是一个有价值的靶点,在各种癌症中高度表达,这将加速基于配体-受体结合的癌症治疗药物的开发。在本研究中,通过组织微阵列分析,我们报告了源自患者的前列腺癌(PCa)组织中叶酸受体表达水平升高,而正常组织中则很少。为了进行基于叶酸受体的 PCa 靶向治疗,我们制备了新型行星球磨(PBM)纳米颗粒(NPs),其中包封了白藜芦醇(RES),并在表面与多西紫杉醇(DTX)结合并与叶酸(FA)偶联。发现 FA 偶联的 DTX-NPs 的细胞毒性作用有效,将游离药物(DTX)的浓度降低至 28 倍。流式细胞术分析显示,FA 偶联的 RES 和与 DTX 纳米颗粒制剂联合使用分别使凋亡细胞数量显著增加 30.92%和 65.9%。然而,仅发现对照(空 NP)中有 8.9%的凋亡细胞。用 FA-RES+DTX-NP 处理后,NF-kB p65、COX-2、促凋亡(BAX、BAK)和抗凋亡(BCL-2、BCL-XL)基因的表达显著降低。此外,FA 偶联的 DTX 制剂在下调 survivin 和增加 PCa 细胞中 cleaved Caspase-3 的表达方面表现出额外的细胞毒性作用。此外,我们观察到用 FA-RES+DTX-NP 处理 DTX 耐药的 PCa 细胞可逆转 ABC 转运蛋白标志物,从而限制了癌细胞的多药耐药表型。我们的结果强烈表明,FA 偶联的纳米药物作为有效的药物外排抑制剂,可有效地增加药物的细胞内浓度,从而发挥其细胞毒性作用。